Abstract
Although vascular endothelial growth factor (VEGF) induces angiogenesis, it also disrupts vascular barrier function in diseased tissues. Accordingly, VEGF expression in cancer and ischaemic disease has unexpected pathophysiological consequences. By uncoupling endothelial cell–cell junctions VEGF causes vascular permeability and oedema, resulting in extensive injury to ischaemic tissues after stroke or myocardial infarction. In cancer, VEGF-mediated disruption of the vascular barrier may potentiate tumour cell extravasation, leading to widespread metastatic disease. Therefore, by blocking the vascular permeability promoting effects of VEGF it may be feasible to reduce tissue injury after ischaemic disease and minimize the invasive properties of circulating tumour cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983)
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003)
Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435–439 (1996)
Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442 (1996)
Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391–400 (2004)
Eliceiri, B. P. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915–924 (1999)
Brown, L. F., Dvorak, A. M. & Dvorak, H. F. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am. Rev. Respir. Dis. 140, 1104–1107 (1989)
van Bruggen, N. et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613–1620 (1999)
Weis, S. et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113, 885–894 (2004)
Paul, R. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nature Med. 7, 222–227 (2001)
Jain, R. K. Transport of molecules across tumour vasculature. Cancer Metastasis Rev. 6, 559–593 (1987)
Dvorak, H. F. Leaky tumour vessels: consequences for tumour stroma generation and for solid tumour therapy. Prog. Clin. Biol. Res. 354A, 317–330 (1990)
Roberts, W. G. & Palade, G. E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369–2379 (1995)
Esser, S. et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. 140, 947–959 (1998)
Feng, D. et al. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6, 23–44 (1999)
Hobbs, S. K. et al. Regulation of transport pathways in tumour vessels: role of tumour type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998)
Monsky, W. L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59, 4129–4135 (1999)
Weis, S., Cui, J., Barnes, L. & Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumour cell extravasation and metastasis. J. Cell Biol. 167, 223–229 (2004)
Salgado, R. et al. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 4, 37–43 (2001)
Cohen, A. W., Carbajal, J. M. & Schaeffer, R. C. Jr VEGF stimulates tyrosine phosphorylation of β-catenin and small-pore endothelial barrier dysfunction. Am. J. Physiol. 277, H2038–H2049 (1999)
Moore, T. M. et al. Receptor-dependent activation of store-operated calcium entry increases endothelial cell permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L691–L698 (2000)
Esser, S., Lampugnani, M. G., Corada, M., Dejana, E. & Risau, W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111, 1853–1865 (1998)
Fischer, S. et al. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am. J. Physiol. 276, C812–C820 (1999)
Chang, Y. S. et al. Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties. Microvasc. Res. 59, 265–277 (2000)
Miles, A. A. & Miles, E. M. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs. J. Physiol. (Lond.) 118, 228–257 (1952)
Liao, F. et al. Selective targeting of angiogenic tumour vasculature by vascular endothelial-cadherin antibody inhibits tumour growth without affecting vascular permeability. Cancer Res. 62, 2567–2575 (2002)
Bates, D. O., Lodwick, D. & Williams, B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 6, 83–96 (1999)
McDonald, D. M., Thurston, G. & Baluk, P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 6, 7–22 (1999)
Feng, D., Nagy, J. A., Dvorak, A. M. & Dvorak, H. F. Different pathways of macromolecule extravasation from hyperpermeable tumour vessels. Microvasc. Res. 59, 24–37 (2000)
Ishida, A. et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J. Cell. Physiol. 188, 359–368 (2001)
Deckers, M. M. et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141, 1667–1674 (2000)
Takahashi, N. et al. Vascular endothelial growth factor induces activation and subcellular translocation of focal adhesion kinase (p125FAK) in cultured rat cardiac myocytes. Circ. Res. 84, 1194–1202 (1999)
Chintalgattu, V., Nair, D. M. & Katwa, L. C. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J. Mol. Cell. Cardiol. 35, 277–286 (2003)
Carmeliet, P. & Storkebaum, E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 13, 39–53 (2002)
Xie, K., Wei, D., Shi, Q. & Huang, S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15, 297–324 (2004)
Reynolds, L. E. et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nature Med. 8, 27–34 (2002)
Friedlander, M. et al. Definition of two angiogenic pathways by distinct αv integrins. Science 270, 1500–1502 (1995)
Eliceiri, B. P. et al. Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signalling. J. Cell Biol. 157, 149–160 (2002)
Robinson, S. D., Reynolds, L. E., Wyder, L., Hicklin, D. J. & Hodivala-Dilke, K. M. β3-Integrin regulates vascular endothelial growth factor-A-dependent permeability. Thromb. Vasc. Biol. 24, 2108–2114 (2004)
Borges, E., Jan, Y. & Ruoslahti, E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain. J. Biol. Chem. 275, 39867–39873 (2000)
Reynolds, A. R. et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signalling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Res. 64, 8643–8650 (2004)
Dejana, E., Corada, M. & Lampugnani, M. G. Endothelial cell-to-cell junctions. FASEB J. 9, 910–918 (1995)
Suarez, S. & Ballmer-Hofer, K. VEGF transiently disrupts gap junctional communication in endothelial cells. J. Cell Sci. 114, 1229–1235 (2001)
Antonetti, D. A., Barber, A. J., Hollinger, L. A., Wolpert, E. B. & Gardner, T. W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274, 23463–23467 (1999)
Pedram, A., Razandi, M. & Levin, E. R. Deciphering vascular endothelial cell growth factor/vascular permeability factor signalling to vascular permeability. Inhibition by atrial natriuretic peptide. J. Biol. Chem. 277, 44385–44398 (2002)
Corada, M. et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl Acad. Sci. USA 96, 9815–9820 (1999)
Kevil, C. G., Okayama, N. & Alexander, J. S. H2O2-mediated permeability II: importance of tyrosine phosphatase and kinase activity. Am. J. Physiol. Cell Physiol. 281, C1940–C1947 (2001)
Nwariaku, F. E. et al. Tyrosine phosphorylation of vascular endothelial cadherin and the regulation of microvascular permeability. Surgery 132, 180–185 (2002)
Lambeng, N. et al. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ. Res. 96, 384–391 (2005)
Suyama, K., Shapiro, I., Guttman, M. & Hazan, R. B. A signalling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2, 301–314 (2002)
Fedor-Chaiken, M., Hein, P. W., Stewart, J. C., Brackenbury, R. & Kinch, M. S. E-cadherin binding modulates EGF receptor activation. Cell Commun. Adhes. 10, 105–118 (2003)
Avizienyte, E., Fincham, V. J., Brunton, V. G. & Frame, M. C. Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to de-regulation of E-cadherin and the epithelial-mesenchymal transition. Mol. Biol. Cell 15, 2794–2803 (2004)
Roura, S., Miravet, S., Piedra, J., Garcia de Herreros, A. & Dunach, M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J. Biol. Chem. 274, 36734–36740 (1999)
Ozawa, M. & Ohkubo, T. Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. J. Cell Sci. 114, 503–512 (2001)
Xu, Y. & Carpenter, G. Identification of cadherin tyrosine residues that are phosphorylated and mediate Shc association. J. Cell. Biochem. 75, 264–271 (1999)
Balsamo, J. et al. Regulated binding of PTP1B-like phosphatase to N-cadherin: control of cadherin-mediated adhesion by dephosphorylation of β-catenin. J. Cell Biol. 134, 801–813 (1996)
Brady-Kalnay, S. M. et al. Dynamic interaction of PTPµ with multiple cadherins in vivo. J. Cell Biol. 141, 287–296 (1998)
Nawroth, R. et al. VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J. 21, 4885–4895 (2002)
Grazia Lampugnani, M. et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, β-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161, 793–804 (2003)
Ukropec, J. A., Hollinger, M. K., Salva, S. M. & Woolkalis, M. J. SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin. J. Biol. Chem. 275, 5983–5986 (2000)
Kroll, J. & Waltenberger, J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272, 32521–32527 (1997)
Wu, H. M., Yuan, Y., Zawieja, D. C., Tinsley, J. & Granger, H. J. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am. J. Physiol. 276, H535–H542 (1999)
Behzadian, M. A. et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 17, 752–754 (2003)
Langille, B. L. Morphologic responses of endothelium to shear stress: reorganization of the adherens junction. Microcirculation 8, 195–206 (2001)
Chen, K. D. et al. Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J. Biol. Chem. 274, 18393–18400 (1999)
Stockton, R. A., Schaefer, E. & Schwartz, M. A. p21-activated kinase regulates endothelial permeability through modulation of contractility. J. Biol. Chem. 279, 46621–46630 (2004)
Wu, M. H., Guo, M., Yuan, S. Y. & Granger, H. J. Focal adhesion kinase mediates porcine venular hyperpermeability elicited by vascular endothelial growth factor. J. Physiol. (Lond.) 552, 691–699 (2003)
Yue, X. & Tomanek, R. J. Stimulation of coronary vasculogenesis/angiogenesis by hypoxia in cultured embryonic hearts. Dev. Dyn. 216, 28–36 (1999)
Marti, H. J. et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 156, 965–976 (2000)
Li, J. et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. 270, H1803–H1811 (1996)
Fukuda, S. et al. Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction. J. Mol. Cell. Cardiol. 36, 547–559 (2004)
Sasaki, H. et al. Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J. Mol. Cell. Cardiol. 34, 335–348 (2002)
Shyu, K. G. et al. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. 54, 576–583 (2002)
Kawamoto, A. et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107, 461–468 (2003)
Kawamoto, A. et al. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110, 1398–1405 (2004)
Lee, R. J. et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102, 898–901 (2000)
Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004)
Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004)
Kuroi, K. & Toi, M. Circulating angiogenesis regulators in cancer patients. Int. J. Biol. Markers 16, 5–26 (2001)
Hormbrey, E. et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis 19, 651–663 (2002)
Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumour xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996)
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004)
Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumour response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004)
Jain, R. K. Normalization of tumour vasculature: An emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005)
Mukhopadhyay, D., Tsiokas, L. & Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161–6165 (1995)
Mukhopadhyay, D. & Datta, K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. 14, 123–130 (2004)
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002)
Baish, J. W., Netti, P. A. & Jain, R. K. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc. Res. 53, 128–141 (1997)
Tsuzuki, Y. et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60, 6248–6252 (2000)
Akiyama, C. et al. Src family kinase inhibitor PP1 improves motor function by reducing edema after spinal cord contusion in rats. Acta Neurochir. Suppl. 86, 421–423 (2003)
Mura, M., dos Santos, C. C., Stewart, D. & Liu, M. Vascular endothelial growth factor and related molecules in acute lung injury. J. Appl. Physiol. 97, 1605–1617 (2004)
Vaquero, J., Chung, C. & Blei, A. T. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann. Hepatol. 2, 12–22 (2003)
Caldwell, R. B. et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab. Res. Rev. 19, 442–455 (2003)
Conklin, B. S., Zhao, W., Zhong, D. S. & Chen, C. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am. J. Pathol. 160, 413–418 (2002)
Zhu, B. Q. et al. Second hand smoke stimulates tumour angiogenesis and growth. Cancer Cell 4, 191–196 (2003)
Liao, H. F. et al. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumour invasion, and metastasis. J. Agric. Food Chem. 51, 7907–7912 (2003)
Tang, F. Y., Nguyen, N. & Meydani, M. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int. J. Cancer 106, 871–878 (2003)
Kimura, Y. & Okuda, H. Resveratrol isolated from Polygonum cuspidatum root prevents tumour growth and metastasis to lung and tumour-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 131, 1844–1849 (2001)
Cao, Z., Fang, J., Xia, C., Shi, X. & Jiang, B. H. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 10, 5253–5263 (2004)
Lin, M. T., Yen, M. L., Lin, C. Y. & Kuo, M. L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol. Pharmacol. 64, 1029–1036 (2003)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.A.C. receives consulting fees and owns stock in TargeGen, Inc., which has developed small molecule inhibitors of vascular permeability.
Rights and permissions
About this article
Cite this article
Weis, S., Cheresh, D. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437, 497–504 (2005). https://doi.org/10.1038/nature03987
Issue Date:
DOI: https://doi.org/10.1038/nature03987
This article is cited by
-
Amphetamine increases vascular permeability by modulating endothelial actin cytoskeleton and NO synthase via PAR-1 and VEGF-R
Scientific Reports (2024)
-
Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease
Journal of Biological Engineering (2023)
-
Differential roles of eNOS in late effects of VEGF-A on hyperpermeability in different types of endothelial cells
Scientific Reports (2023)
-
Alcohol and breast cancer
Pharmacological Reports (2023)
-
Modeling angiogenesis in the human brain in a tissue-engineered post-capillary venule
Angiogenesis (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.